Avoro Capital Advisors Adds $14M in Ocular Therapeutix, Inc. ($OCUL)

Avoro Capital Advisors has increased its stake in Ocular Therapeutix, Inc. (NasdaqGM: OCUL) by 14.3%, according to its latest 13F filing with the SEC. The fund added 1,537,223 shares, bringing its total holdings to 12,315,000 shares valued at approximately $110.1 million as of the reporting period.

What Changed in Avoro Capital's Ocular Therapeutix Position

Avoro Capital Advisors grew its position in Ocular Therapeutix by adding approximately 1.54 million shares. This boost brought its total holdings to about 12.32 million shares, marking a 14.3% increase from its previous 10.78 million shares. The value of Avoro's investment in Ocular Therapeutix now stands at roughly $110.1 million.

Other Institutional Activity in Ocular Therapeutix

Several other funds also adjusted their positions in Ocular Therapeutix. FMR LLC increased its holdings by 868,159 shares, ending with 32,653,764 shares worth about $276.6 million. Deep Track Capital, LP made a significant move, adding 11,615,868 shares to reach a total of 19,686,282 shares valued at $166.7 million. BlackRock, Inc. grew its stake by 530,537 shares, bringing its total to 16,132,931 shares valued at approximately $136.6 million. Meanwhile, Summer Road LLC added 771,270 shares, reaching a total of 11,879,825 shares worth around $100.6 million.

Ocular Therapeutix Stock Snapshot

Shares of Ocular Therapeutix traded near $8.94. The company has a market cap of about $1.96 billion. Its forward P/E ratio isn't meaningful as the company is not currently profitable. With a beta of 0.896, the stock has a 52-week low of $6.23 and a high of $16.44. The 50-day moving average is $8.95, and the 200-day moving average is $10.58. The company maintains a strong liquidity position with a current ratio of 14.81 and a quick ratio of 14.49, alongside a debt-to-equity ratio of 13.66.

Recent Earnings

Ocular Therapeutix reported revenue of $52.04 million, with a modest growth of 0.8%. However, the company is not yet profitable, posting a negative return on equity of -68.55% and a net margin of 0.0%. The next earnings report is expected on August 5, 2026.

Insider Buying and Selling at Ocular Therapeutix, Inc.

Recent insider activity at Ocular Therapeutix includes several purchases. On June 10, 2026, Adrienne Graves bought 44,000 shares. Jason Shand Robins, the CFO, acquired 14,024 shares. Other insiders like Seung Suh Hong and Richard Lindstrom also made purchases, each buying 14,000 shares.

Analysts Set New Price Targets

Analysts have been active with Ocular Therapeutix. On May 6, 2026, RBC Capital reiterated its 'buy' rating with a price target of $30. HC Wainwright & Co. also reiterated a 'buy' rating, setting a target of $21 on April 13, 2026. The consensus among analysts is a 'strong buy' with an average price target of $26, based on 11 opinions.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing treatments for eye diseases using its hydrogel-based technology. Headquartered in Bedford, Massachusetts, the company markets DEXTENZA for post-surgical ocular inflammation and pain, and is developing other therapies like AXPAXLI and OTX-TIC for conditions such as macular degeneration and glaucoma. Led by CEO Dr. Pravin U. Dugel, the company employs around 325 people.

Bottom Line

Investors are closely watching Ocular Therapeutix as Avoro Capital Advisors and other major funds adjust their positions. The company's innovative treatments and ongoing clinical trials make it a notable player in the biotechnology sector. However, it's important to remember that 13F filings are backward-looking and may not reflect current holdings.